HemaCare is the leading global provider of human-derived cellular material, supplying controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood, bone marrow, and cord blood. HemaCare supports biotechnology and pharmaceutical companies, academic institutions, and research organization who rely on high-quality, viable, and functional human primary cells and blood components for biomedical and drug discovery research and cell therapy development.
Corporate Reports and Filings
News and Events
HemaCare will be exhibiting at the ISSCR 2019 Annual Meeting. Be sure to stop by our booth, number 535, to learn more about our products and how HemaCare can support your stem cell research needs.READ MORE
CAR-T Congress USA
HemaCare will present as part of the session on “Novel Approaches to CAR-T Process Development” on Wednesday, April 17 at 3:30 pm. Visit us at booth #14 to meet the HemaCare team and to discuss how our high-quality, customizable cell therapy solutions can help advance your research projects.READ MORE
HemaCare and Tissue Solutions Announce Strategic Partnership to Expand Access to Human Disease-State SamplesHemaCare and Tissue Solutions Announce Strategic Partnership to Expand Access to Human Disease-State SamplesREAD MORE
Investor Relations Contact Information
(877) 310-0717 (option 8)
250 Royall Street
Canton, MA 02021
The statements contained in this website which are not historical facts are forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company’s control, with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission.
HemaCare voluntarily delisted from NASDAQ in 2012 due to the significant costs of remaining a public company and is no longer required to be registered with the SEC. HemaCare is currently traded on the OTCMKTS (Pink Sheets) under “HEMA”.
Note: It is the policy of HemaCare not to respond to email inquiries via return email. If you have a specific question regarding HemaCare, please call.